Vanguard Group Inc. boosted its position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) by 2.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 657,101 shares of the biotechnology company’s stock after buying an additional 17,657 shares during the quarter. Vanguard Group Inc. owned approximately 3.51% of Brainstorm Cell Therapeutics worth $2,733,000 at the end of the most recent reporting period.

Separately, Sphera Funds Management LTD. acquired a new position in Brainstorm Cell Therapeutics in the 2nd quarter valued at $2,759,000. 13.08% of the stock is owned by institutional investors.

Brainstorm Cell Therapeutics Inc. (NASDAQ BCLI) opened at $4.04 on Wednesday. Brainstorm Cell Therapeutics Inc. has a 12 month low of $2.10 and a 12 month high of $5.18.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings results on Tuesday, October 17th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. During the same quarter last year, the business earned ($0.09) earnings per share. analysts forecast that Brainstorm Cell Therapeutics Inc. will post -0.37 earnings per share for the current fiscal year.

Separately, Maxim Group set a $9.00 target price on shares of Brainstorm Cell Therapeutics and gave the company a “buy” rating in a research note on Monday, October 16th.

ILLEGAL ACTIVITY WARNING: “Vanguard Group Inc. Has $2.73 Million Stake in Brainstorm Cell Therapeutics Inc. (BCLI)” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.watchlistnews.com/vanguard-group-inc-has-2-73-million-stake-in-brainstorm-cell-therapeutics-inc-bcli/1746552.html.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Want to see what other hedge funds are holding BCLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI).

Receive News & Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.